It is stunning to me that someone pays for something, they don't get it, but the person or the entity they paid it to still gets to keep it.
Anna Eshoo
The Public Record
Anna A. Eshoo is an American politician serving as the U.S. Representative for California's 16th congressional district since 2013. A member of the Democratic Party, she has been an advocate for various issues including healthcare, technology, and environmental protection. Eshoo has played a significant role in shaping policies related to telecommunications and has been involved in efforts to improve access to healthcare for her constituents.
★ Featured Quote
June 20, 2023
I want to ask you if you will consider STAs and if you will commit to providing the public transparency that is really due because this is a huge issue?
— Anna Eshoo
Chairwoman Rosenworcel, for as long as I can remember, you have been in my view the leading voice about the need to close the digital divide and the homework gap.
We need more guardrails in place on AI, which is why I introduced the Real Political Ads Act earlier this month.
I've long been a champion for protecting vulnerable communities from the harms that come with new technologies.
You did a great job, and I think that you answered--with your answers you were highly instructive to all of the members of the committee.
I think that, you know, to a person--well, maybe not to a--well, just--I am getting myself in a little trouble here.
We need to get a clear explanation from hospitals on why, after hospitals acquire physician practices, the prices for the services provided by the acquired physicians increases by 14 percent.
I find it hypocritical when I hear time and time and time again that plans are often blocked by PBMs from offering the lowest-priced generic.
I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.
The Medicaid Value-Based Payments for Patients Act will codify a CMS rule to help ensure Medicaid enrollees have access to breakthrough gene therapies.
This is, as you said and have said many times, this is a devastating disease, and I don't think this can be treated as 17 months of a little additional hope.
The PBM Accountability Act will finally shed a light on the opaque drug pricing system.
In 1997 this subcommittee held a joint hearing with the Senate Labor Committee to review our Nation's system for organ transplant.
I support the legislation we are considering today to permanently authorize the THC GME program and fund new training sites to increase resident physician spots.





